A pre-clinical organoid model to select suitable bladder cancer patients for targeting EZH2 treatment

被引：0
|
作者：
Zhao, H. [1 ]
Liao, J. [2 ]
Liu, K. [1 ]
Chen, X. [1 ]
Wu, H. [1 ]
Chiu, P. K-F [1 ]
Ng, C-F [1 ]
Teoh, J. Y-C [1 ]
机构：
[1] Chinese Univ Hong Kong, Dept Surg, Hong Kong, Peoples R China
[2] Chinese Univ Hong Kong, Dept Chem Pathol, Hong Kong, Peoples R China
来源：
EUROPEAN UROLOGY | 2024年 / 85卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
A0592
引用
收藏
页码：S1501 / S1501
页数：1
相关论文
共 50 条
  • [21] THE RELATION BETWEEN EZH2 EXPRESSION AND CLINICAL OUTCOMES IN COLORECTAL CANCER PATIENTS TREATED WITH ANTI-EGFR THERAPEUTICS
    Yamamoto, Itaru
    Nosho, Katsuhiko
    Kurihara, Hiroyoshi
    Igarashi, Hisayoshi
    Kanno, Shinichi
    Ishigami, Keisuke
    Koide, Hideyuki
    Mitsuhashi, Kei
    Sukawa, Yasutaka
    Okita, Kenji
    Takemasa, Ichiro
    Yamamoto, Hiroyuki
    Shinomura, Yasuhisa
    Nakase, Hiroshi
    GASTROENTEROLOGY, 2017, 152 (05) : S1027 - S1027
  • [22] Exploring the anti-cancer potential of SGLT2 inhibitors in breast cancer treatment in pre-clinical and clinical studies
    Naeimzadeh, Yasaman
    Tajbakhsh, Amir
    Nemati, Mahnaz
    Fallahi, Jafar
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2024, 978
  • [23] Cell panel profiling of pre-clinical and clinical anti-cancer agents reveals conserved therapeutic clusters and differentiates the mechanism of action of different PI3K/mTOR, Aurora kinase and EZH2 inhibitors
    Uitdehaag, J. C. M.
    De Roos, J. A. D. M.
    Prinsen, M. B. W.
    Willemsen-Seegers, N.
    De Vetter, J. R. F.
    Dylus, J.
    Van Doornmalen, A. M.
    Kooijman, J.
    Sawa, M.
    Van Gerwen, S. J. C.
    De Man, J.
    Buijsman, R. C.
    Zaman, G. J. R.
    EUROPEAN JOURNAL OF CANCER, 2016, 69 : S24 - S24
  • [24] Pre-clinical investigation of a novel investigational new drug, SHetA2, for the treatment of vulvar cancer
    Duininck, Grace
    Garland, Justin
    Lausen, James
    Mortan, Laura
    Bohn, Jacqueline
    Benbrook, Doris
    GYNECOLOGIC ONCOLOGY, 2024, 190 : S230 - S231
  • [25] Synergistic pre-clinical activity of combined epigenetic therapy with the EZH2 antagonist 3-Deazaneplanocinand HDAC inhibitor panobinostat against human AML and Mantle Cell Lymphoma cells
    Fiskus, Warren
    Wang, Yongchao
    Rao, Rekha
    Yang, Yonghua
    Chen, Jianguang
    Joshi, Atul
    Koul, Sanjay
    Upadhyay, Sunil
    Balusu, Ramesh
    Fernandez, Pravina
    Joshi, Rajeshree
    Buckley, Kate
    Jillella, Anand
    Ustun, Celalettin
    Atadja, Peter
    Marquez, Victor
    Bhalla, Kapil
    CANCER RESEARCH, 2009, 69
  • [26] Bispecific T Cell Engager (BiTE) Targeting IL13Rα2 Improves Survival in a Pre-Clinical Model of Glioblastoma. Bispecific T Cell Engager (BiTE) Targeting IL13Rα2 Improves Survival in a Pre-Clinical Model of Glioblastoma
    Zannikou, Markella
    Pituch, Katarzyna C.
    Ilut, Liliana
    Balyasnikova, Irina V.
    MOLECULAR THERAPY, 2019, 27 (04) : 267 - 267
  • [27] Synergistic Pre-Clinical Activity of Combined Epigenetic Therapy with the Novel Histone Methyltransferase EZH2 Inhibitor 3-Deazaneplanocin and Histone Deacetylase Inhibitor Panobinostat against Human AML Cells
    Fiskus, Warren
    Wang, Yongchao
    Jillella, Anand
    Ustun, Celalettin
    Johnston, Pace
    Joshi, Rajeshree
    Rao, Rekha
    Ataja, Peter
    Marquez, Victor
    Bhalla, Kapil N.
    BLOOD, 2008, 112 (11) : 1152 - 1152
  • [28] A crucial epithelial to mesenchymal transition regulator, Sox4/Ezh2 axis is closely related to the clinical outcome in pancreatic cancer patients
    Hasegawa, Shinichiro
    Nagano, Hiroaki
    Konno, Masamitsu
    Eguchi, Hidetoshi
    Tomokuni, Akira
    Tomimaru, Yoshito
    Asaoka, Tadafumi
    Wada, Hiroshi
    Hama, Naoki
    Kawamoto, Koichi
    Marubashi, Shigeru
    Nishida, Naohiro
    Koseki, Jun
    Mori, Masaki
    Doki, Yuichiro
    Ishii, Hideshi
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2016, 48 (01) : 145 - 152
  • [29] 2,2-dimethylbenzopyran derivatives containing pyridone structural fragments as selective dual-targeting inhibitors of HIF-1α and EZH2 for the treatment of lung cancer
    Xu, Huashen
    Zhang, Jie
    Zhuang, Junning
    Chen, Yuanguang
    Chen, Lu
    Wang, Jianmin
    Cao, Ruolin
    Liu, Fuqin
    Wang, Kaibo
    Zhang, Xiaoyu
    Wang, Lihui
    Chen, Guoliang
    BIOORGANIC CHEMISTRY, 2024, 147
  • [30] Pre-clinical validation of a pan-cancer CAR-T cell immunotherapy targeting nfP2X7
    Bandara, Veronika
    Foeng, Jade
    Gundsambuu, Batjargal
    Norton, Todd S.
    Napoli, Silvana
    Mcpeake, Dylan J.
    Tyllis, Timona S.
    Rohani-Rad, Elaheh
    Abbott, Caitlin
    Mills, Stuart J.
    Tan, Lih Y.
    Thompson, Emma J.
    Willet, Vasiliki M.
    Nikitaras, Victoria J.
    Zheng, Jieren
    Comerford, Iain
    Johnson, Adam
    Coombs, Justin
    Oehler, Martin K.
    Ricciardelli, Carmela
    Cowin, Allison J.
    Bonder, Claudine S.
    Jensen, Michael
    Sadlon, Timothy J.
    Mccoll, Shaun R.
    Barry, Simon C.
    NATURE COMMUNICATIONS, 2023, 14 (01)
12345